(Reuters) -The U.S. health regulator on Friday approved the expanded use of BioMarin Pharmaceutical's once-daily injection to treat children under the age of 5 with the most common form of ...

May 20 (Reuters) - BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to short stature helped boost growth in children, meeting the main goal of a late-stage study ...

The Food and Drug Administration approved the first treatment for the most common cause of dwarfism Friday, a drug that has proved to increase children’s height but has been polarizing among adults ...

BioMarin has won the FDA's go-ahead for its next big launch. But the drug's arrival may be unwelcome news for those who've built a community out of living full lives with dwarfism. The FDA approved ...

BioMarin Pharmaceuticals Inc. BMRN stock is trading higher on Thursday as the company is celebrating positive results from ...

(Reuters) - U.S.-based Biomarin Pharmaceutical Inc's treatment for one of the most common forms of dwarfism received clearance from the European Commission, becoming the first therapy to get an ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The drug has been in high demand ...

(Reuters) - BioMarin Pharmaceutical Inc said its experimental drug was effective in improving growth in children with the most common form of dwarfism in a mid-stage study. The company's shares rose 6 ...

Shares of Ascendis Pharma ASND rose 17% on Monday after it reported top-line results from the pivotal ApproaCH study that evaluated investigational once-weekly administered TransCon CNP in children ...

After nearly 25 years of operating at a loss, BioMarin hopes to finally turn a corner and post its first profits in 2022 as the commercial launch of dwarfism drug Voxzogo kicks into gear. But some ...